Kenvue Inc. (NYSE:KVUE) Given Average Recommendation of "Hold" by Brokerages

Shares of Kenvue Inc. (NYSE:KVUE - Get Free Report) have been given a consensus recommendation of "Hold" by the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $24.00.

A number of equities research analysts have recently weighed in on KVUE shares. Canaccord Genuity Group boosted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. UBS Group cut their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and decreased their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th.

Kenvue Stock Up 1.4 %

KVUE traded up $0.30 on Friday, hitting $21.79. The company had a trading volume of 22,035,170 shares, compared to its average volume of 16,916,348. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market capitalization of $41.65 billion, a price-to-earnings ratio of 41.11, a P/E/G ratio of 2.62 and a beta of 1.02. The stock has a fifty day moving average price of $22.61 and a 200-day moving average price of $22.42. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts predict that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.76%. Kenvue's payout ratio is 154.72%.

Institutional Trading of Kenvue

Institutional investors have recently bought and sold shares of the business. Grove Bank & Trust grew its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in Kenvue during the fourth quarter valued at $29,000. SRS Capital Advisors Inc. grew its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC increased its stake in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.